Sorrento Therapeutics, Inc. (SRNE) recently closed with fall of -1.27% to its 20-Day Simple Moving Average. This short time frame picture represents a downward movement of current price over average price of last 20 days. Now moving toward intermediate time frame, 50-day Moving average is more useful at showing position trading trends lasting 50 days. Shares of SRNE moved downward with change of -16.05% to its 50-day Moving average. This falling movement shows negative prices direction over last 50 days.
The bulls say this is a great opportunity to buy Sorrento, citing a reasonable price for a solid, growth stock. Among the near-term catalysts that can boost the stock value, analysts note great strategic partnerships and a strong pipeline. Many traders are betting that Sorrento Therapeutics will become a key player in the immuno-oncology (I/O) space.
The bears are skeptical about the convertible debt that the company incurred, as well as less attractive financing deals. J Capital Research asserts that the financing deals have benefited a select group of investors who are close to the CEO.
Good to buy?
The bulls say this is a great opportunity to buy Sorrento, citing a reasonable price for a solid, growth stock. Among the near-term catalysts that can boost the stock value, analysts note great strategic partnerships and a strong pipeline. Many traders are betting that Sorrento Therapeutics will become a key player in the immuno-oncology (I/O) space.
The bears are skeptical about the convertible debt that the company incurred, as well as less attractive financing deals. J Capital Research asserts that the financing deals have benefited a select group of investors who are close to the CEO.
Good to buy?
